PATENT CLAIM ANALYSIS

Application Number: 16166220
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["530", "391900"]

Abstract:
Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.

Claim (Index 15):
The method of  claim 14 , wherein the cancer is selected from the group consisting of gastric cancer, lung cancer, bladder cancer, breast cancer, pancreatic cancer, renal cancer, colorectal cancer, cervical cancer, ovarian cancer, brain tumor, prostate cancer, hepatocellular carcinoma, melanoma, esophageal carcinoma, multiple myeloma, and head and neck squamous cell carcinoma.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 97.0
- Lexical Diversity: 1.68519
- Patent Class: 530.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15037104', '15018710', '14518294', '14734957', '14517682']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7217025598867144
- 35 USC 102 Novelty (BERT): 0.5322202633823303
- Combined Prediction Score: 0.702754330236276
- Mean Citation Score: 345.902172
- Max Citation Score: 358.13632
- Similarity Product: 292.38357728424074

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test